PDS0204 / PDS Biotech, Farmacore - LARVOL DELTA

PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune-Based COVID-19 Vaccine with an Award of up to Approximately US$60 million (GlobeNewswire) - "PDS Biotechnology Corporation...has received a commitment...to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil. MCTI intends to start making the funds available to prepare to perform a combined Phase 1/2 clinical trial...The pre-IMPD package for the Phase 1/2 trial is currently under review by Anvisa and the trial is anticipated to begin by Q2/3 2021....The consortium anticipates working to initiate manufacturing scale up activities in the second quarter....The Phase 1 and 2 trials, which will be run together, are anticipated to enroll approximately 360 patients..."

Financing • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease

"$PDSB ER on 11/11 AH, CC on Thursday PM Lock up period for previous offering ends Wednesday...no coincidence imo. 10Q never filed later than 11/7 in 5 years. On watch for big news related to funding/partnership, PDS0204 preclinical data, Ph2 triple combo study update" (@MisterLongBuck)

Licensing / partnership • Preclinical